0.79%
-1.30%
-24.50%
-65.58%
-59.39%
-75.76%
100.10%
AI Spotlight on MRNA
Company Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.
It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc.and changed its name to Moderna, Inc.in August 2018.
Moderna, Inc.was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 41.04 |
| Change Percentage | 0.79% |
| Open | 41.4 |
| Previous Close | 40.72 |
| Market Cap ( Millions) | 15793 |
| Volume | 12206227 |
| Year High | 170.47 |
| Year Low | 31.94 |
| M A 50 | 40.62 |
| M A 200 | 83.39 |
Financial Ratios
| FCF Yield | -25.05% |
| Dividend Yield | 0.00% |
| ROE | -17.68% |
| Debt / Equity | 11.36% |
| Net Debt / EBIDTA | 13.97% |
| Price To Book | 1.32 |
| Price Earnings Ratio | -7.1 |
| Price To FCF | -3.99 |
| Price To sales | 3.11 |
| EV / EBITDA | -7.5 |
News
- Jan -30 - Ethris Presents Positive Topline Phase 1 Data with mRNA Lead Candidate ETH47 for Uncontrolled Asthma
- Jan -29 - Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
- Jan -29 - Moderna Stock Falls on Vaccine Revenue Concerns
- Jan -29 - Moderna's stock is falling. Goldman Sachs says it's no longer a buy.
- Jan -29 - The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
- Jan -29 - Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
- Jan -27 - Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
- Jan -27 - 5 Stocks That Powered S&P 500 ETF in Trump's First Week
- Jan -25 - Why Moderna Stock Jumped Over 20% This Week
- Jan -25 - 3 Things You Need to Know if You Buy Moderna Today
- Jan -25 - 3 Beaten-Down Stocks That Haven't Been This Cheap in More Than 3 Years: Are They Bargain Buys?
- Jan -24 - Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
- Jan -23 - A norovirus vaccine could be on the horizon as cases rise
- Jan -22 - Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines
- Jan -22 - Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines
- Jan -22 - After a Reset Year, Is Moderna Stock Poised for a Comeback?
- Jan -21 - 3-Stock Lunch: 3M, Moderna, & T-Mobile
- Jan -21 - Why Is Moderna Stock Trading Higher On Tuesday?
- Jan -21 - Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
- Jan -21 - Underperforming Moderna Stock Boosted by Bird Flu Vaccine
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Messenger RNA (mRNA) Medicines
Expected Growth : 10.95 %
What the company do ?
Messenger RNA (mRNA) medicines from Moderna, Inc. use genetic instructions to direct cells to produce proteins, enabling the body to prevent or fight diseases.
Why we expect these perspectives ?
Moderna's mRNA medicines growth is driven by increasing demand for COVID-19 vaccines, expansion into new therapeutic areas such as cancer and rare diseases, strategic partnerships, and advancements in mRNA technology enabling improved efficacy and safety profiles.
Moderna, Inc. Products
| Product Range | What is it ? |
|---|---|
| mRNA-1273 (COVID-19 Vaccine) | A vaccine against COVID-19, encoding for a prefusion stabilized spike protein |
| mRNA-4157 (Vaccine against VEGF-A) | A vaccine against vascular endothelial growth factor A (VEGF-A), a protein involved in angiogenesis |
| mRNA-4151 (Vaccine against OX40L) | A vaccine against OX40L, a protein involved in T cell activation and immune response |
| mRNA-528 (Vaccine against IL-23) | A vaccine against interleukin-23 (IL-23), a protein involved in autoimmune diseases |
| mRNA-2752 (Vaccine against CMV) | A vaccine against cytomegalovirus (CMV), a common viral infection |
| mRNA-1647 (Vaccine against RSV) | A vaccine against respiratory syncytial virus (RSV), a common cause of respiratory illness |
Moderna, Inc.'s Porter Forces
Threat Of Substitutes
Moderna's mRNA technology provides a unique value proposition, making it difficult for substitutes to emerge.
Bargaining Power Of Customers
While customers have some bargaining power due to the availability of alternative vaccine options, Moderna's strong brand reputation and innovative products mitigate this force.
Bargaining Power Of Suppliers
Moderna has a diversified supplier base, reducing dependence on individual suppliers and minimizing the bargaining power of suppliers.
Threat Of New Entrants
The COVID-19 pandemic has accelerated the development of mRNA technology, attracting new entrants to the market, increasing competition, and posing a significant threat to Moderna's market share.
Intensity Of Rivalry
The COVID-19 vaccine market is highly competitive, with multiple players vying for market share, leading to intense rivalry and pricing pressure.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 8.23% |
| Debt Cost | 3.95% |
| Equity Weight | 91.77% |
| Equity Cost | 11.75% |
| WACC | 11.11% |
| Leverage | 8.97% |
Moderna, Inc. : Quality Control
Moderna, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who … |
| IMNM | Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of … |
| REGN | Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular … |
| PRAX | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive … |
| GTHX | G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Vertex Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Regeneron Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Praxis Precision Medicines
A-Score
1-Year Total Return ->
4
Moderna
A-Score
1-Year Total Return ->
5
G1 Therapeutics
A-Score
1-Year Total Return ->
6
